Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The management believes that this move shall enable value unlocking of the core business (pharmaceuticals) and enhance long-term growth. Further, it also provides operational flexibility, focused and dedicated management (for respective businesses), different brand positioning for each legal entity.
As a part of the proposed reorganization, the Company may retain a small minority stake in the resulting company. This is to support the company in terms of common services such as R&D, Patents, etc. Support via Transitional Service Agreements (TSAs) at arm's length pricing.
Natco Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 852.8, down 0.16% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.23% on the day, quoting at 24998.35. The Sensex is at 81448.84, down 0.33%.Natco Pharma Ltd has eased around 0.29% in last one month.Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has increased around 0.34% in last one month and is currently quoting at 22180.7, down 0.52% on the day. The volume in the stock stood at 2.37 lakh shares today, compared to the daily average of 3.88 lakh shares in last one month.
The PE of the stock is 9.12 based on TTM earnings ending June 25.
The company expressed confidence in addressing the observations within the stipulated timeline and reaffirmed its commitment to cGMP compliance and supplying high-quality products to its global customers and patients.
NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.
The company’s consolidated net profit fell 28.1% to Rs 480.70 crore in Q1 FY26, compared with Rs 668.50 crore in Q1 FY25. Revenue from operations declined 2.5% YoY to Rs 1,328.90 crore in Q1 FY26.